

**Biology and technology contribution to clinical advancement: the case of oropharyngeal cancer**

**Brescia – May 8<sup>th</sup>, 2009**

**SURGERY FOR THE TREATMENT  
OF OROPHARYNGEAL CARCINOMA:  
STATE OF ART**

***Piero Nicolai***



Department of Otorhinolaryngology  
University of Brescia



# TNM Classification of Malignant Tumours

## International Union Against Cancer (UICC) (6<sup>th</sup> Edition, 2002)

### OROPHARYNX

**T3:** Tumor more than 4 cm in greatest dimension

**T4a:** Tumor invades the larynx, deep/extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible

**T4b:** Tumor invades lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, or skull base; or encases carotid artery

**unresectable (or incurable?)**




# OROPHARYNGEAL CARCINOMA

## PRE-TREATMENT EVALUATION

**Clinical examination:** duration of symptoms  
referred otalgia  
tongue mobility  
trismus  
infiltrating vs exophytic lesion  
comorbidities (!)

**Radiologic examination (MR/CT):** soft tissue extension  
**Functional imaging (PET/CT)** mandibular involvement  
pterygoid muscles and plates  
styloid muscles  
hypoglossal nerve(s)  
lingual arterie(s)  
nasopharynx  
"N" status (+US)



# OROPHARYNGEAL CARCINOMA

## MANDIBULAR INVOLVEMENT

	<b>OPG*</b>	<b>CT#</b>	<b>SPET°</b>	<b>SPECT*</b>	<b>MRI^</b>
<b>SENSITIVITY</b>	<b>50%</b>	<b>96%</b>	<b>95%</b>	<b>95%</b>	<b>93%</b>
<b>SPECIFICITY</b>	<b>94%</b>	<b>87%</b>	<b>48%</b>	<b>72%</b>	<b>93%</b>
<b>PPV</b>	<b>91%</b>	<b>89%</b>	<b>65%</b>	<b>79%</b>	<b>88%</b>
<b>NPV</b>	<b>63%</b>	<b>95%</b>	<b>93%</b>	<b>93%</b>	<b>96%</b>

\* : Imola et al., Laryngoscope 2001

# : Mukherji et al., AJR 2001

° : Zieron et al., Head Neck 2001

^ : Bolzoni et al., Arch Otolaryngol Head Neck Surg 2004



# OROPHARYNGEAL CARCINOMA

## CRITERIA FOR PRIMARY TREATMENT SELECTION

- Surgery
- Concomitant CHT-RT



Resectable vs “unresectable” lesions

Loss of function (total glossectomy, total laryngectomy)

Exophytic vs infiltrating lesions

Presence of massive necrosis

Mandibular involvement

Retropharyngeal mets

Comorbidities


Induction chemotherapy (?)

Biological markers (?)



# OROPHARYNGEAL CARCINOMA

p53 - p105Rb: interaction with HPV



- HPV (16) infection more frequent in NSND (p=0.003)
- HPV infection more frequent in laryngeal and oropharyngeal cancer (p=0.02)
- Overexpression and no mutations of p53 in NSND

Fouret et al, Arch Otolaryngol Head Neck Sur 1997;123:513-516





# OROPHARYNGEAL CARCINOMA

## Role of HPV 16

- HPV positive status affects OS ( $p=0.002$ ), incidence of tumor relapse ( $p=0.03$ ), and second tumors ( $p=0.01$ )

Licitra et al, J Clin Oncol 2006

- Assessment of HPV, p53, p16, and EGFR status may be crucial in order to obtain more tailored and beneficial treatments for oropharyngeal cancer

Perrone et al, Clin Cancer Res 2006



# OROPHARYNGEAL CARCINOMA

## HPV, EGFR

- 64% of cases positive for HPV
- Always younger patients
- HPV titer was significantly associated to a better response to induction CHT, better OS, better DSS
- Intensity of EGFR expression significantly correlated with poor response to induction CHT and poor OS
- EGFR expression inversely correlated to HPV titer
- All non-smokers were HPV +
- High EGFR/HPV- patients had the worse prognosis

Kumar et al, Int J Radiat Oncol Biol Phys 2007





# OROPHARYNGEAL CARCINOMA

## Role of HPV 16

- HPV presence was associated with:
  - Younger age ( $p=0.016$ )
  - Nonsmoking status ( $p=0.037$ )
  - A greater proportion of men ( $p=0.08$ )
  - Better response to induction chemotherapy ( $p=0.003$ )
  - Better response to CHT-RT ( $p=0.005$ )
  - Better OS ( $p=0.007$ ) and DSS ( $p=0.008$ )

Worden et al, J Clin Oncol 2008



# OROPHARYNGEAL CARCINOMA

## FACTORS AFFECTING TREATMENT RESPONSE AND DFS

- T- status
- N- status
- Stage
- Subsite of primary

T1-T4 lesions:  
2-yr recurrence rate

N0	50% (11/13 pure regional)
N1	59%
N2	65%
N3	82%
<b>Total</b>	<b>62%</b>

Sundaram et al. Laryngoscope 2005


### 5-yr DFS for stage IV base of tongue SCC

Riley et al., 1983	14% (BOT)
Levy et al., 1991	0% (BOT)
Weber et al., 1993	0% (BOT)
Hinerman, et al., 1994	35% (only T4 BOT)
Sundaram, et al., 2005	66% (T3) 28% (T4) <small>*All subsites</small>



# OROPHARYNGEAL CARCINOMA

## CHOICE OF TREATMENT



# OROPHARYNGEAL CARCINOMA

## CHEMOTHERAPY

Diagnosis

Primary treatment

### Neo-adjuvant CHT

Several meta-analyses demonstrated its inefficacy in improving 5-yr survival. However, it could predict the response to RT in organ preservation protocols.

Browman et al, Head Neck 2001  
Worden et al, ASCO 2005

### Concomitant CHT

It can be associated with different RT regimens:

- Conventional RT
- Hyperfractionated RT
- Accelerated RT
- Continuous RT
- Split RT

### Adjuvant CHT

It does not seem to modify survival by itself; however, in association with RT is able to improve local-regional control, DFS, and to delay distant metastases (with higher toxicity)


Cooper et al. N Engl J Med 2004  
Bernier et al. N Engl J Med 2004



# OROPHARYNGEAL CARCINOMA

## INDUCTION OR NEO-ADJUVANT CHEMOTHERAPY

Continuous infusion (day 1 - 4): Cisplatin 25 mg/m<sup>2</sup> + 5-FU 750 mg/m<sup>2</sup>  
3-hour infusion (day 2): paclitaxel 135-175 mg/m<sup>2</sup>



# OROPHARYNGEAL CARCINOMA

## SALVAGE SURGERY

Efficacy correlated with:

- Recurrence stage ( $p=0.0005$ )
- Recurrent site ( $p=0.06$ ; worse for oroph and neck)
- Not at all with time to presalvage recurrence ( $p=NS$ )

Goodwin, Laryngoscope 2000





# PERSONAL SERIES

## JANUARY 1994 - DECEMBER 2003

### STAGE III/IV OROPHARYNGEAL CANCER

N° pts: **50**

Mean age: **56.2** (range, 36-71)

Male/female ratio: **44/6**

Histology: **49** SCC, 1 MEC

Previous treatment: **21 pts** (42%)

### SURVIVALS (Kaplan-Meier method)

Overall survival (5-yr): **32.2%**  $\pm$  7.2

Determinate survival (5-yr): **36.9%**  $\pm$  7.5



# STATISTICAL ANALYSIS

## UNIVARIATE (Log rank test)

**Stage:  $p=0.2$**



Stage III:  $48.5\% \pm 16.6$

Stage IV:  $34.6\% \pm 8.4$

**Previous treatment:  $p=0.0001$**

Primary surgery:  $62.9\% \pm 10.2$

Salvage surgery:  $5.1\% \pm 5.0$






# SURGICAL APPROACHES

## MANDIBULAR SWING

The mandible is splitted to improve exposure of the lesion and to better delineate surgical margins of resection

Advanced lesions with marginal involvement of the lateral wall not reaching the medial pterygoid muscle




# SURGICAL APPROACHES

## MANDIBULAR SWING

The distance between the lateral incisor and the canine was 1-6.2 mm, while the distance between the two central incisors ranged from 0.5 to 4.7 mm ( $p < 0.05$ ).

Moreover, midline mandibulotomy requires detachment of multiple muscles (digastric, mylohyoid, geniohyoid, genioglossus) which may lead to masticatory and swallowing problems

Shohat et al, Int J Oral Maxillofac Surg 2005








# SURGICAL APPROACHES



## MANDIBULAR RESECTION

A part of the mandible is resected "en bloc" with the tumor when direct involvement is suspected, or because of its close proximity to the deep resection margin


Advanced recurrent lesions of the lateral pharyngeal wall are mostly resected together with a part of the mandible



**Segmental resection**





**Marginal resection**



# SURGICAL APPROACHES


## PULL-THROUGH





# RECONSTRUCTIVE SURGERY

## MAIN TARGETS AND OPTIONS

To allow resections otherwise not feasible  
To optimize "residual" functions:   
To improve "residual" quality of life

Velo-palatal competence  
Effective swallowing  
Mandibular continuity

### ~~PEDICLED FLAPS~~

  
Pectoralis major  
Upper trapezius  
Lower trapezius  
Latissimus dorsi

### FREE FLAPS

Forearm  
Rectus abdominis (DIEP)  
Anterolateral thigh (ALT)  
Lateral arm  
Iliac crest  
Fibula





# RECONSTRUCTIVE OPTIONS

## PEDICLED FLAPS

### When and why...


- Severe comorbidities
- Vascular diseases
- Diabetes (?)
- Salvage surgery (?)
- Free flap failure
- Personal confidence



# RECONSTRUCTIVE OPTIONS


## FOREARM FREE FLAP (FFF)

### Soft palate




Combined with pharyngo-palatal synechia

### Lateral wall



### Base of tongue





# RECONSTRUCTIVE OPTIONS

## RECTUS ABDOMINIS (DIEP)

### ▪ **PERFORATOR FLAP**

- This is not a new microsurgical technique but rather an improvement due to a refinement in the understanding of the anatomy
- It requires a more thorough dissection of the flap but no change in the microsurgical technique

- Anatomic variability of perforators
- Difficulty of the operation
- Length of time
- Higher risk for total failure








# RECONSTRUCTIVE OPTIONS

## ANTERO-LATERAL TIGHT (ALT)

- Acceptance is limited by:
  - Tedious dissection
  - Length of time
  - Perforators abnormalities






# RECONSTRUCTIVE OPTIONS


## ILIAC CREST and FIBULA

Mandibular reconstruction represents a crucial issue in the following situations:

- Young dentate patients
- Good prognosis
- Able to financially support dental implants



**20-40%** of cutaneous plate exposure for anterior defects. For limited lateral defects, in case of plate exposure, recurrent disease has to be excluded





# CONCLUSIONS

- T3-T4 lesions of the oropharynx often have a dismal prognosis
- Factors affecting treatment response and DFS are: high stage, with special reference to “N” status, and subsite of the primary (worse local-regional control for base of tongue)
- Patients treated for persistent or recurrent lesions have an extremely poor outcome (5-yr DSS: 5.1%;  $p=0.0001$ )



# CONCLUSIONS

- Transmandibular approach with paramedian mandibulotomy is considered the gold-standard for oropharyngeal lesions in view of a favourable exposure and minimal morbidity
- Reconstructive options should be tailored according to patient's age, body habitus, comorbidities, and prognosis
- In general, free flaps lead to better functional outcomes, with the radial forearm being the ideal choice for lateral wall and soft palate defects, and DIEP and ALT for subtotal and total glossectomies



# OPEN ISSUES

- Is there agreement on the imaging studies required to select the adequate treatment?
- Should biological markers (HPV 16, p53, EGFR) be routinely used for treatment selection?
- Is there a role for induction chemotherapy in treatment selection?
- Which is the role of EGFR inhibitors?
- Do we have information concerning how many patients can not complete a concomitant regimen of chemo-radiation because of acute toxicity?
- Are there enough data to compare residual quality of life of patients submitted to organ preservation protocols vs that of patients treated by surgery and post-op chemo-RT?

